| Document |
Document Title |
|
11913000 |
The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
|
|
EP4159220A1 |
Methods of treating complement-mediated ocular disorders by administering agents that inhibit a subject's complement component in an amount sufficient to treat the ocular disorder wherein, in a selected embodiment, said agent is an anti-...
|
|
11273171 |
The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with anothe...
|
|
11208663 |
Aptamers that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprising the aptamers and aptamer constructs are p...
|
|
20210369757 |
The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with anothe...
|
|
20210332361 |
The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
|
|
JP6949916B2 |
Aptamers having improved stability against nucleases that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprisi...
|
|
JP6914284B2 |
Aptamers that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprising the aptamers and aptamer constructs are p...
|
|
10947544 |
The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
|
|
20200056181 |
Aptamers that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprising the aptamers and aptamer constructs are p...
|
|
10544419 |
Aptamers having improved stability against nucleases that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprisi...
|
|
JP2020010716A |
To provide aptamers having improved stability against nucleases that bind PDGF, and aptamers that bind VEGF.The invention relates to nucleic acid molecules, such as aptamers, including specific nucleotide sequences and including a C-5 mo...
|
|
JP6587934B2 |
Aptamers that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprising the aptamers and aptamer constructs are p...
|
|
20190185858 |
The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
|
|
JP2019068851A |
To provide aptamers useful for preventing and treating disorders in which PDGF and/or VEGF has been implicated.An aptamer comprises a sequence: 5'-NZVSLnS'V'ZACNNmGCGZZZAZAGCG-3' (SEQ ID NO: 500), wherein V is selected from an A, C or G;...
|
|
10221421 |
Aptamers that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprising the aptamers and aptamer constructs are p...
|
|
20180258432 |
Aptamers having improved stability against nucleases that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprisi...
|
|
EP3360582A1 |
Methods of treating complement-mediated ocular disorders by administering agents that inhibit a subject's complement component in an amount sufficient to treat the ocular disorder wherein, in a selected embodiment, said agent is an anti-...
|
|
9994857 |
Aptamers having improved stability against nucleases that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprisi...
|
|
20170260531 |
Aptamers that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprising the aptamers and aptamer constructs are p...
|
|
20170247702 |
Aptamers having improved stability against nucleases that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprisi...
|
|
9701967 |
Aptamers that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprising the aptamers and aptamer constructs are p...
|
|
9695424 |
Aptamers having improved stability against nucleases that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprisi...
|
|
EP3165606A1 |
This invention relates to methods and compositions useful for the treatment or prevention of an ophthalmological disease, comprising administration of an effective amount of a PDGF antagonist and a VEGF antagonist to a mammal in need the...
|
|
9617546 |
The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
|
|
20160298118 |
Aptamers that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprising the aptamers and aptamer constructs are p...
|
|
20160177307 |
Aptamers having improved stability against nucleases that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprisi...
|
|
EP3034094A1 |
Methods of treating complement-mediated ocular disorders by administering agents that inhibit a subject's complement component in an amount sufficient to treat the ocular disorder wherein, in a selected embodiment, said agent is an anti-...
|
|
EP3028707A1 |
This invention relates to methods and compositions useful for the treatment or prevention of an ophthalmological disease, comprising administration of an effective amount of a PDGF antagonist and a VEGF antagonist to a mammal in need the...
|
|
9234202 |
Nuclease-resistant RNA aptamers are provided which are capable of neutralizing PDGFRβ and are therefore useful in the diagnosis and/or therapy of PDGFRβ-associated and hyperproliferative-associated diseases, such as cancer and primary ...
|
|
EP2596807B1 |
Methods of treating complement-mediated ocular disorders by administering agents that inhibit a subject's complement component in an amount sufficient to treat the ocular disorder wherein, in a selected embodiment, said agent is an anti-...
|
|
20150275215 |
Nuclease-resistant RNA aptamers are provided which are capable of neutralizing PDGFRβ and are therefore useful in the diagnosis and/or therapy of PDGFRβ-associated and hyperproliferative-associated diseases, such as cancer and primary ...
|
|
JP2015517806A |
Aptamers that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs containing PDGF aptamer and VEGF are provided. Pharmaceutical compositions containing these aptamers and aptamer constructs are provided al...
|
|
20150159158 |
The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
|
|
8946184 |
The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
|
|
8853376 |
Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and VEGF receptor or any combination thereof with great affinity and spec...
|
|
WO/2014/053640A1 |
The present invention provides a nuclease -resistant RNA aptamer which is capable of neutralizing PDGFRβ and is therefore useful in the diagnosis and/or therapy of PDGFRβ associated hyperproliferative associated diseases, such as cance...
|
|
EP2716761A1 |
The present invention provides a nuclease-resistant RNA aptamer which is capable of neutralizing PDGFRβ and is therefore useful in the diagnosis and/or therapy of PDGFRß associated hyperproliferative associated diseases, such as cancer...
|
|
8685397 |
The invention features methods for treating a patient diagnosed with, or at risk of developing, a neovascular disorder by administering a PDGF antagonist and a VEGF antagonist to the patient. The invention also features a pharmaceutical ...
|
|
20130237589 |
The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
|
|
EP2596807A1 |
Methods of treating complement-mediated ocular disorders by administering agents that inhibit a subject's complement component in an amount sufficient to treat the ocular disorder wherein, in a selected embodiment, said agent is an anti-...
|
|
8436164 |
The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
|
|
EP2432476A4 |
This invention relates to methods and compositions useful for the treatment or prevention of an ophthalmological disease, comprising administration of an effective amount of a PDGF antagonist and a VEGF antagonist to a mammal in need the...
|
|
20120322860 |
The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
|
|
8236773 |
The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
|
|
20120171304 |
Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and VEGF receptor or any combination thereof with great affinity and spec...
|
|
EP2432476A1 |
This invention relates to methods and compositions useful for the treatment or prevention of an ophthalmological disease, comprising administration of an effective amount of a PDGF antagonist and a VEGF antagonist to a mammal in need the...
|
|
7964572 |
Methods are described for the identification and preparation of high-affinity Nucleic Acid Ligands to Complement System Proteins. Methods are described for the identification and preparation of high affinity Nucleic Acid Ligands to Compl...
|
|
20110060027 |
The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
|
|
20100129364 |
The invention features methods for treating a patient diagnosed with, or at risk of developing, a neovascular disorder by administering a PDGF antagonist and a VEGF antagonist to the patient. The invention also features a pharmaceutical ...
|
